Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2012

01-07-2012 | Letter to the Editor

Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria

Authors: Akihiro Tomita, Yukari Shirasugi, Takahiko Ito, Hisashi Tsurumi, Tomoki Naoe

Published in: Annals of Hematology | Issue 7/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Luzzatto L, Gianfaldoni G, Notaro R (2011) Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol 153(6):709–720CrossRef
2.
Berzuini A, Montanelli F, Prati D (2010) Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 363(10):993–994CrossRef
3.
Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, Richards SJ, Bessler M, Bell L, Hillmen P, Gladwin MT (2010) Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 149(3):414–425CrossRef
4.
Risitano AM, Notaro R, Luzzatto L, Hill A, Kelly R, Hillmen P (2010) Paroxysmal nocturnal hemoglobinuria–hemolysis before and after eculizumab. N Engl J Med 363(23):2270–2272CrossRef
5.
Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, Ricci P, Alfinito F, Camera A, Gianfaldoni G, Amendola A, Boschetti C, Di Bona E, Fratellanza G, Barbano F, Rodeghiero F, Zanella A, Iori AP, Selleri C, Luzzatto L, Rotoli B (2009) Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113(17):4094–4100CrossRef
Metadata
Title
Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria
Authors
Akihiro Tomita
Yukari Shirasugi
Takahiko Ito
Hisashi Tsurumi
Tomoki Naoe
Publication date
01-07-2012
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 7/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1368-z

Other articles of this Issue 7/2012

Annals of Hematology 7/2012 Go to the issue

Original Article

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients

Original Article

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases

Original Article

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Original Article

Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major

Original Article

Unstable hemoglobin Rush [beta 101(G3) Glu>Gln, HBB:c.304G>C] in a Brazilian family with moderate hemolytic anemia

Letter to the Editor

Aberrant expression of myeloid and B cell markers in an aggressive multiple-site myeloid sarcoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits